Adding one year of Imfinzi treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone
The survey revealed that the proportion of individuals experiencing constant thoughts about food throughout the day declined by 46 percent after starting Wegovy
The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options
Nadda noted that on the basis of economic caste census, 50 crore people were brought under this scheme
For people with relapsed or refractory diffuse large B-cell lymphoma
Globally, colorectal cancer impacts 1.9 million people each year, standing as a leading cause of cancer mortality
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia.
Subscribe To Our Newsletter & Stay Updated
